

Title

Electroencephalographic signatures of migraine in small prospective and large retrospective cohorts

Authors

Bihua Bie¹, Samer Ghosn¹, Shehryar R Sheikh^{1,2}, Matheus Lima Diniz Araujo³, Reena Mehra⁴, MaryAnn Mays⁵, Carl Y. Saab^{1,6*}


**Corresponding author*

Affiliations

1. Department of Biomedical Engineering, Cleveland Clinic, Cleveland, OH, USA.
2. Department of Neurosurgery, Cleveland Clinic, Cleveland, OH, USA
3. Sleep Disorder Center, Cleveland Clinic and Biomedical Engineering, Lerner Research Institute
4. Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington
5. Center for Neurologic Restoration, Neurologic Institute, Cleveland Clinic, Ohio, Cleveland, USA
6. Department of Engineering, Brown University, Providence, RI, USA

**Corresponding author*

Carl Y. Saab, Department of Biomedical Engineering, Cleveland Clinic Foundation, Cleveland, OH, USA. Email: saabc@ccf.org



Supp Fig 1

S. Figure 1: No difference in EEG features between episodic and chronic migraine subjects

Averaged PSDs in all-electrodes montage in the range of 4-20 Hz (delta, theta, alpha, and beta bands) in episodic versus chronic migraine groups showed no significant difference across 4 bands (1-32 Hz).

Supplementary Table 1a. Demographic information for participants in Supp Fig 1

	Control	Chronic	Episodic
Number	25	24	13
Age (years)	32.1 ± 2.5	39.5 ± 2.8	36.2 ± 2.7
Gender (F/M)	15/10	22/2 ^{##}	10/3

^{##} P<0.01 control vs. chronic

Supplementary Table 1b. Medical information for participants in Supp Fig 1

	Chronic	Episodic
Duration (years)	14.8 ± 2.6	11.3 ± 2.3
Pain during recording	3.3 ± 0.7	4.3 ± 1.1
PHQ-9	7.8 ± 1.2	7.2 ± 1.2
MIDAS	82.1 ± 23.0	17.1 ± 3.4 (p<0.01)
HIT-6	63.4 ± 1.5	60.5 ± 3.4
Nausea	1.5 ± 0.5	3.4 ± 0.9
Sensitive to light	3.3 ± 0.7	4.1 ± 1.1
Sensitive to sound	2.0 ± 0.65	4.2 ± 1.1
Poor concentration (Yes/No)	12/12	5/8
Word finding/language (Yes/No)	8/16	3/10
Dizziness (Yes/No)	6/18	3/10
Visual abnormalities (Yes/No)	8/16	0/13 (p<0.01)
Tingling/ numbness (Yes/No)	6/18	3/10
Weakness (Yes/No)	4/20	3/10

Supplementary Table 1c. Medication history for participants in Supp Fig 1

Items	Chronic	Episodic
Participant number	24	13
PRN doses in the last month	12.9 $\pm$ 8.3	7.5 $\pm$ 1.6
Medication for acute attack		
Triptans	20	11
CGRP Antagonists	2	3
Anti-emetics	9	5
OTCs (Tylenol, NSAIDS)	11	2
Steroids (methylprednisolone, dexamethasone)	3	2
Medication for prophylactics		
Anti Epileptics' (Topiramate, Valproate)	14	2
Beta Blockers	3	3
Botox	6	0
CGRP Antagonists	3	3
Antidepressants	1	1
Verapamil	1	0
Gabapentin	3	1
Supplements (Magnesium, Riboflavin)	4	3